CEGEDIM SA (CGM.PA) Stock Fundamental Analysis
EPA:CGM - Euronext Paris - Matif - FR0000053506 - Common Stock - Currency: EUR
CGM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 10 industry peers in the Health Care Technology industry. CGM has a bad profitability rating. Also its financial health evaluation is rather negative. CGM has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
CGM had negative earnings in the past year.
In the past year CGM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CGM reported negative net income in multiple years.
CGM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CGM has a worse Return On Assets (-1.49%) than 60.00% of its industry peers.
With a Return On Equity value of -5.56%, CGM is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Looking at the Return On Invested Capital, with a value of 4.46%, CGM is in line with its industry, outperforming 50.00% of the companies in the same industry.
CGM had an Average Return On Invested Capital over the past 3 years of 2.87%. This is below the industry average of 7.31%.
The 3 year average ROIC (2.87%) for CGM is below the current ROIC(4.46%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROIC | 4.46% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
1.3 Margins
With a Operating Margin value of 5.75%, CGM is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of CGM has declined.
The Gross Margin of CGM (20.07%) is worse than 90.00% of its industry peers.
CGM's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% |
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CGM is creating some value.
CGM has more shares outstanding than it did 1 year ago.
CGM has less shares outstanding than it did 5 years ago.
CGM has a worse debt/assets ratio than last year.
2.2 Solvency
CGM has an Altman-Z score of 1.27. This is a bad value and indicates that CGM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CGM (1.27) is comparable to the rest of the industry.
CGM has a debt to FCF ratio of 27.31. This is a negative value and a sign of low solvency as CGM would need 27.31 years to pay back of all of its debts.
The Debt to FCF ratio of CGM (27.31) is comparable to the rest of the industry.
CGM has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
CGM has a Debt to Equity ratio of 1.14. This is in the lower half of the industry: CGM underperforms 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Altman-Z | 1.27 |
ROIC/WACC1.1
WACC4.06%
2.3 Liquidity
A Current Ratio of 0.99 indicates that CGM may have some problems paying its short term obligations.
The Current ratio of CGM (0.99) is worse than 70.00% of its industry peers.
CGM has a Quick Ratio of 0.99. This is a bad value and indicates that CGM is not financially healthy enough and could expect problems in meeting its short term obligations.
CGM's Quick ratio of 0.97 is on the low side compared to the rest of the industry. CGM is outperformed by 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The earnings per share for CGM have decreased strongly by -97.97% in the last year.
The Revenue has been growing slightly by 6.25% in the past year.
The Revenue has been growing slightly by 5.38% on average over the past years.
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
3.2 Future
CGM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.45% yearly.
The Revenue is expected to grow by 3.51% on average over the next years.
EPS Next Y30.09%
EPS Next 2Y24.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.92%
Revenue Next 2Y3.51%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 7.21, the valuation of CGM can be described as very cheap.
Based on the Price/Forward Earnings ratio, CGM is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, CGM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.21 |
4.2 Price Multiples
CGM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CGM is cheaper than 100.00% of the companies in the same industry.
CGM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CGM is cheaper than 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.64 | ||
| EV/EBITDA | 3.26 |
4.3 Compensation for Growth
CGM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CGM's earnings are expected to grow with 24.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.45%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CGM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:CGM (6/20/2025, 7:00:00 PM)
10.7
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners17.29%
Inst Owner ChangeN/A
Ins Owners57.12%
Ins Owner ChangeN/A
Market Cap150.87M
Analysts48.89
Price Target13.26 (23.93%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.88%
PT rev (3m)-14.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-6.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.21 | ||
| P/S | 0.23 | ||
| P/FCF | 12.64 | ||
| P/OCF | 1.48 | ||
| P/B | 0.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.26 |
EPS(TTM)-1.07
EYN/A
EPS(NY)1.48
Fwd EY13.88%
FCF(TTM)0.85
FCFY7.91%
OCF(TTM)7.22
OCFY67.51%
SpS46.42
BVpS18.75
TBVpS-11.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROCE | 6.06% | ||
| ROIC | 4.46% | ||
| ROICexc | 4.84% | ||
| ROICexgc | 19.22% | ||
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% | ||
| FCFM | 1.82% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
ROICexc(3y)3.13%
ROICexc(5y)4.15%
ROICexgc(3y)11.62%
ROICexgc(5y)15.26%
ROCE(3y)3.91%
ROCE(5y)5.29%
ROICexcg growth 3Y0.21%
ROICexcg growth 5Y-3.19%
ROICexc growth 3Y-3.24%
ROICexc growth 5Y-2.52%
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
F-Score3
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Debt/EBITDA | 2.3 | ||
| Cap/Depr | 96.22% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 4.24 | ||
| Cash Conversion | 77.7% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 1.27 |
F-Score3
WACC4.06%
ROIC/WACC1.1
Cap/Depr(3y)92.57%
Cap/Depr(5y)94.88%
Cap/Sales(3y)13.24%
Cap/Sales(5y)13.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
EPS Next Y30.09%
EPS Next 2Y24.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
Revenue Next Year2.92%
Revenue Next 2Y3.51%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y79.81%
EBIT growth 3Y0.5%
EBIT growth 5Y1.66%
EBIT Next Year278.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-46.81%
FCF growth 3Y-27.43%
FCF growth 5YN/A
OCF growth 1Y4.01%
OCF growth 3Y2%
OCF growth 5Y28.33%